Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges: 2020-2022

Historic Amortization of Deferred Charges for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Sep 2022 value amounting to $1,000.

  • Insight Molecular Diagnostics' Amortization of Deferred Charges fell 92.31% to $1,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $22,000, marking a year-over-year decrease of 67.65%. This contributed to the annual value of $12,000 for FY2022, which is 78.57% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Amortization of Deferred Charges of $1,000 as of Q3 2022, which was down 75.00% from $4,000 recorded in Q2 2022.
  • In the past 5 years, Insight Molecular Diagnostics' Amortization of Deferred Charges registered a high of $35,000 during Q1 2020, and its lowest value of $1,000 during Q3 2022.
  • Over the past 3 years, Insight Molecular Diagnostics' median Amortization of Deferred Charges value was $14,000 (recorded in 2021), while the average stood at $15,455.
  • Data for Insight Molecular Diagnostics' Amortization of Deferred Charges shows a maximum YoY slumped of 92.31% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Insight Molecular Diagnostics' Amortization of Deferred Charges stood at $22,000 in 2020, then plummeted by 54.55% to $10,000 in 2021, then plummeted by 92.31% to $1,000 in 2022.
  • Its last three reported values are $1,000 in Q3 2022, $4,000 for Q2 2022, and $7,000 during Q1 2022.